Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
McGill University
$27,000.00
Overcoming Chemoresistance in HPV-Positive Oropharyngeal Cancer: From Mechanistic Insights to Targeted Therapies
FY 2025-26
Summary
Human Papillomavirus (HPV)-positive oral cancer is increasing in Canada and around the world, now representing 35% of all oral cancer cases. Standard treatments, such as radiotherapy combined with chemotherapy, often lead to permanent side effects and a reduced quality of life. Our department is investigating a promising alternative: neoadjuvant chemotherapy (NCT), which is given before surgery to shrink tumors. In our clinical trial, 72% of patients showed no remaining cancer at the primary tumor site after NCT, indicating a complete response.
However, some patients respond only partially. Based on genetic sequencing from trial participants, we believe that these patients have distinct gene expression patterns that influence treatment resistance. Our research will explore these gene expression patterns (Aim 1) and test new therapies to overcome resistance (Aim 2).
Aim 1: We will silence 14 genes that were found to be differently expressed in patients with partial treatment responses. Using HPV-positive oral cancer cell lines, we will assess how silencing these genes affects cell survival, growth, and response to chemotherapy.
Aim 2: Building on Aim 1, we will test novel targeted therapies, both alone and in combination with chemotherapy, to re-sensitize resistant cancer cells.
By identifying new treatment strategies in the lab, we aim to pave the way for better clinical outcomes and improved quality of life for patients facing HPV-positive oral cancer.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
572752
Name
Fraser Sara
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Overcoming Chemoresistance in HPV-Positive Oropharyngeal Cancer: From Mechanistic Insights to Targeted Therapies
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cell Lines; Chemotherapy; Drug Resistance; Gene Knockdown; Head And Neck Cancer; Human Papillomavirus; Targeted Therapy
Abstract
Human Papillomavirus (HPV)-positive oral cancer is increasing in Canada and around the world, now representing 35% of all oral cancer cases. Standard treatments, such as radiotherapy combined with chemotherapy, often lead to permanent side effects and a reduced quality of life. Our department is investigating a promising alternative: neoadjuvant chemotherapy (NCT), which is given before surgery to shrink tumors. In our clinical trial, 72% of patients showed no remaining cancer at the primary tumor site after NCT, indicating a complete response.
However, some patients respond only partially. Based on genetic sequencing from trial participants, we believe that these patients have distinct gene expression patterns that influence treatment resistance. Our research will explore these gene expression patterns (Aim 1) and test new therapies to overcome resistance (Aim 2).
Aim 1: We will silence 14 genes that were found to be differently expressed in patients with partial treatment responses. Using HPV-positive oral cancer cell lines, we will assess how silencing these genes affects cell survival, growth, and response to chemotherapy.
Aim 2: Building on Aim 1, we will test novel targeted therapies, both alone and in combination with chemotherapy, to re-sensitize resistant cancer cells.
By identifying new treatment strategies in the lab, we aim to pave the way for better clinical outcomes and improved quality of life for patients facing HPV-positive oral cancer.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fraser, Sara
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~